PUBLISHED ON: December 21, 2015 | Duration: 1 min, 29 sec
Sarabjit Kour Nangra of Angel Broking said the brokerage has been vouching Sun Pharma as a buy since the stock corrected to 720-730 levels as the market had factored in issues related to the Halol unit. Our view has not changed, she added.
